<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393522</url>
  </required_header>
  <id_info>
    <org_study_id>SAV-MD-25</org_study_id>
    <nct_id>NCT01393522</nct_id>
  </id_info>
  <brief_title>Milnacipran for Migraine Pain</brief_title>
  <official_title>A Randomized Double Blind Placebo Control Trial of Milnacipran for Migraine Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Smith</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if milnacipran taken twice daily is effective in
      reduction of headache pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating Headache Pain Reduction</measure>
    <time_frame>Will report change from baseline after the 90 day reporting period</time_frame>
    <description>To evaluate the efficacy of milnacipran in headache pain reduction in subjects with chronic migraine (CM) without fibromyalgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating the improvement of Quality of Life</measure>
    <time_frame>Changes from Visit 1 quality of life until study completion month 4</time_frame>
    <description>To evaluate the efficacy of milnacipran in improving quality of life in subjects with chronic migraine (CM) without fibromyalgia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Migraine Prevention</measure>
    <time_frame>Will assess at day 30, day 60 and day 90</time_frame>
    <description>To evaluate the efficacy of milnacipran in migraine prevention in subjects with chronic migraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep and Energy</measure>
    <time_frame>Will assess at visit 2 and again at visit 5, study completion visit</time_frame>
    <description>To evaluate the impact of milnacipran on sleep and energy in subjects with chronic migraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression</measure>
    <time_frame>At screening visit 1, visit 2, visit 3, visit 4 and visit 5 study completion</time_frame>
    <description>To evaluate the relationship of baseline anxiety and depression on the efficacy of milnacipran for the above outcome measures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>Milnacipran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then will taper down.</description>
    <arm_group_label>Milnacipran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet will be titrated 1 tablet once a day increased per protocol to 2 tablets twice a day, with a starting dose of 12.5mg per day to 50 mg twice a day</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals between the age of 18 and 65

          -  Headache fulfills ICHD-2 criteria for: chronic migraine, or probable medication
             overuse headache where individual headaches meet criteria for migraine

          -  At least 15 headache days/month and at least 8 migraine or probable migraine
             days/month for the past 3 months, by patient report (including days of headache
             relieved with a triptan or related compound).

          -  Age at onset of chronic migraine &lt; 60 years old

        Exclusion Criteria:

          -  Pregnancy or attempting conception

          -  Unable to read or write English

          -  Use of Opiates &gt;/= 10 days per month

          -  Subject has failed &gt;/= 4 adequate preventive trials of antidepressant medications due
             to lack of efficacy; at least one trial included another SNRI.(An adequate preventive
             trial defined as at least 6 weeks on therapeutic dose [150mg of amitriptyline or
             nortriptyline or other tricyclic, 150mg of venlafaxine, 60mg of duloxetine])

          -  Subjects on antidepressant medications, including SNRIs who cannot safely withdraw
             from those medications, in the assessment of the PI. Subjects on other headache
             preventives (beta blockers, antiepileptic drugs), at stable dose for at least three
             months, will be allowed to participate.

        A. Subjects on other headache preventives may be included in the study if the medication
        has been at a stable dose for 3 months.

          -  Presence of fibromyalgia or another pain or medical disorder that would make it
             difficult for patient to distinguish headache-related quality of life from overall
             health related quality of life.

          -  Uncontrolled or unstable psychiatric disorder (PHQ-9 score or GAD-7 score &gt;15 with
             sentinel questions &gt;/=4, or in opinion of examiner), or anticipated need for change in
             psychotropic medications during duration of study period; or suicidality.

          -  Chronic kidney disease, liver disease, or any poorly controlled medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Wellness Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Research</investigator_affiliation>
    <investigator_full_name>Timothy Smith</investigator_full_name>
    <investigator_title>Vice President of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>headache</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 24, 2015</submitted>
    <returned>October 26, 2015</returned>
    <submitted>October 30, 2015</submitted>
    <returned>December 4, 2015</returned>
    <submitted>December 21, 2015</submitted>
    <returned>January 29, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

